|07 October, 2018

Neopharma continues with its Global journey; acquires a manufacturing facility in US from Dr. Reddy's Laboratories

The Bristol site has had a long history first with the British drug maker GlaxoSmithKline (GSK) and then with Dr. Reddy's in manufacturing the brands Augmentin® and Amoxil®.

Abu Dhabi, UAE - Neopharma Inc., USA, a subsidiary of Abu Dhabi based UAE’ largest pharmaceutical manufacturer, Neopharma LLC, announced that in a 100% ownership transfer, it has acquired from Dr. Reddy’s Laboratories, Inc. a subsidiary of Dr. Reddy’s Laboratories Ltd. an antibiotic manufacturing facility and its related assets in Bristol, Tennessee (US).

The Bristol site has had a long history first with the British drug maker GlaxoSmithKline (GSK) and then with Dr. Reddy’s in manufacturing the brands Augmentin® and Amoxil®. The sale will enable the facility to continue providing oral penicillin-containing antibacterial products to patients in the United States. The 390,000-square-foot facility is dedicated to manufacturing and packaging oral-solid dose penicillin and has separate spaces for processing, packaging, development, printing, and warehousing.

Currently Neopharma has 5 globally accredited pharmaceutical manufacturing facilities in 3 continents and serves over 50 countries with 100+ different products.

Dr. B.R. Shetty, Founder & Chairman, Neopharma remarked “We are delighted to have this acquisition from Dr. Reddy’s Laboratories as the acquisition follows similar acquisitions made in Japan, Brazil and India and is a part of the global expansion drive for Neopharma, which is rapidly establishing itself as a global manufacturer of quality medications at affordable prices. The acquisition will strengthen the UAE’s presence in the global pharma space”.

Suresh Kumar Nandiraju, Chief Operating Officer of Neopharma, said, “This acquisition allows us to enter the United States penicillin-containing antibiotic market segment and marks our entry into the generic drug business in the US while providing opportunities to explore additional synergies with our other group companies. The acquisition will help us leverage our expertise in beta lactam manufacturing segment.” 

Beta lactam is a class of broad-spectrum antibiotics, consisting of all antibiotic agents that contain a beta-lactam ring in their molecular structures.

About Neopharma: 

Neopharma LLC, is one of the largest pharmaceutical companies in the MENA region. Neopharma is a vertically integrated business, providing economies of scale and with an extremely skilled team, Neopharma is able to deliver quality products in a timely manner at affordable prices in over 50 countries worldwide. Neopharma's global presence is supported by 5 manufacturing facilities spread across 3 continents delivering a wide range of branded and generic formulations, and active pharmaceutical ingredients (APIs).  The therapeutic segments covered by our portfolio of over 100 high-quality molecules include anti-infectives, neurology, cardiology, orthopedics, diabetology, gastroenterology, urology, dermatology, gynecology, respiratory, dental and nutritionals. Neopharma LLC also has 100% subsidiaries in Japan, India, Brazil, Russia, UK and USA

For further information, log on to: www.neopharma.com

About Neopharma Inc.: 

Neopharma Inc. is a wholly owned, subsidiary of Abu Dhabi based, Neopharma LLC and was established in 2017 in Princeton, New Jersey. Core objectives of the company includes development, manufacturing and marketing of pharmaceuticals in USA and LATAM markets. The major therapeutic areas of focus are anti-infectives, cardiovascular, diabetology, oncology, respiratory & pain management.

About Dr. Reddy’s: 

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. The major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. The major markets include – USA, India, Russia & CIS countries, and Europe. 

For more information, log on to: www.drreddys.com

Enquiries:

Neopharma LLC; Tel: +9712 550 1000 

www.neopharma.com

neopharma@neopharma.ae

© Press Release 2018

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases